Lipford GB - Search Results

1

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model.

Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, van der Burg SH, Melief CJ. Vambutas A, et al. Among authors: lipford gb. Vaccine. 2005 Nov 1;23(45):5271-80. doi: 10.1016/j.vaccine.2005.04.049. Epub 2005 Jul 11. Vaccine. 2005. PMID: 16054734

2

Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.

Welters MJ, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn AR, van der Marel GA, Overkleeft HS, Lipford G, Offringa R, Melief CJ, van Boom JH, van der Burg SH, Drijfhout JW. Welters MJ, et al. Vaccine. 2004 Dec 2;23(3):305-11. doi: 10.1016/j.vaccine.2004.06.008. Vaccine. 2004. PMID: 15530672

3

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.

Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ. Zwaveling S, et al. Among authors: lipford gb. J Immunol. 2002 Jul 1;169(1):350-8. doi: 10.4049/jimmunol.169.1.350. J Immunol. 2002. PMID: 12077264

4

Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells.

Ossendorp F, Fu N, Camps M, Granucci F, Gobin SJ, van den Elsen PJ, Schuurhuis D, Adema GJ, Lipford GB, Chiba T, Sijts A, Kloetzel PM, Ricciardi-Castagnoli P, Melief CJ. Ossendorp F, et al. Among authors: lipford gb. J Immunol. 2005 Jun 15;174(12):7815-22. doi: 10.4049/jimmunol.174.12.7815. J Immunol. 2005. PMID: 15944286

5

Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells.

Lipford GB, Wagner H, Heeg K. Lipford GB, et al. Vaccine. 1994 Jan;12(1):73-80. doi: 10.1016/0264-410x(94)90013-2. Vaccine. 1994. PMID: 8303944

6

In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability.

Lipford GB, Bauer S, Wagner H, Heeg K. Lipford GB, et al. Vaccine. 1995 Feb;13(3):313-20. doi: 10.1016/0264-410x(95)93320-9. Vaccine. 1995. PMID: 7631520

7

Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.

Bauer S, Heeg K, Wagner H, Lipford GB. Bauer S, et al. Among authors: lipford gb. Scand J Immunol. 1995 Sep;42(3):317-23. doi: 10.1111/j.1365-3083.1995.tb03662.x. Scand J Immunol. 1995. PMID: 7660065

8

CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.

Vabulas RM, Pircher H, Lipford GB, Häcker H, Wagner H. Vabulas RM, et al. Among authors: lipford gb. J Immunol. 2000 Mar 1;164(5):2372-8. doi: 10.4049/jimmunol.164.5.2372. J Immunol. 2000. PMID: 10679072

9

CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses.

Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. Lipford GB, et al. J Immunol. 2000 Aug 1;165(3):1228-35. doi: 10.4049/jimmunol.165.3.1228. J Immunol. 2000. PMID: 10903720

10

Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.

Lipford GB, Hoffman M, Wagner H, Heeg K. Lipford GB, et al. J Immunol. 1993 Feb 15;150(4):1212-22. J Immunol. 1993. PMID: 7679422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters